Baltimore, MD51 Active Studies

Osteogenesis Imperfecta Clinical Trials in Baltimore, MD

Find 51 actively recruiting osteogenesis imperfecta clinical trials in Baltimore, MD. Connect with local research sites and explore new treatment options.

51
Active Trials
31
Sponsors
11,444
Enrolling

Recruiting Osteogenesis Imperfecta Studies in Baltimore

About Osteogenesis Imperfecta Clinical Trials in Baltimore

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 51 osteogenesis imperfecta clinical trials recruiting participants in Baltimore, MD. These studies are seeking a combined 11,444 participants. Research is being sponsored by Beat AML, LLC, Alnylam Pharmaceuticals, Baylor College of Medicine and 28 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Baltimore — FAQ

Are there osteogenesis imperfecta clinical trials in Baltimore?

Yes, there are 51 osteogenesis imperfecta clinical trials currently recruiting in Baltimore, MD. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Baltimore?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Baltimore research site will contact you about next steps.

Are clinical trials in Baltimore free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Baltimore studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 51 active trials in Baltimore are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated July 13, 2026 from ClinicalTrials.gov